Altintas, R.Oguz, F.Beytur, A.Ediz, C.Gunes, A.Ozer, A.2024-08-042024-08-0420130210-48061699-7980https://doi.org/10.1016/j.acuro.2012.11.018https://hdl.handle.net/11616/96260Purpose: We investigated retrospectively the clinical outcomes of the patients with type III inflammatory chronic prostatitis, who were treated with fluoroquinolones with and without an alpha-blocker between 2009-2011. Material and methods: Diagnosis was established with medical history (symptoms presented Longer than 3 months within previous 6 months), physical examination, Meares-Stamey test and the questionnaire of the NIH-CPSI. The responses to the treatment were assessed with uroflowmetry test and the questionnaire of NIH-CPSI at initial and after 4 weeks of the treatment. The patients with incomplete data and treatment and who treated with alpha-blockers and/or antibiotics in the period 4 weeks prior to the therapy started in our clinic and had any surgery of lower urinary tract previously were excluded. The patients were classified under 6 groups; group1 = ciprofloxacin, group2 = ofloxacin, group3 = levofloxacin, group4 = ciprofloxacin+tamsulosin, group5 = ofloxacin+tamsulosin, group 6 = levofloxacin+tamsulosin. Wilcoxon Signed Ranks and Kruskal Wallis test were used for comparison of results. Mann Whitney U test with Bonferroni correction made was used as posthoc (P < .05). Results: The median scores of NIH-CPSI decreased significantly in all groups (P < .05). Levofloxacin reduced the median total scores of NIH-CPSI more than ciprofloxacin and ofloxacin monotherapies. The combination therapies were better than antibiotic therapies alone and best result was obtained in levofloxacin + tamsulosin combination. Conclusion: Tamsulosin + fluoroquinolone (especially tamsulosin + levofloxacin) combinations yielded better results in both NIH-CPSI scores and peak flow rates. (C) 2012 AEU. Published by Elsevier Espana, S.L. All rights reserved.esinfo:eu-repo/semantics/closedAccessFluoroquinolonesAlpha blockerChronic prostatitisArticle37106196242376850410.1016/j.acuro.2012.11.0182-s2.0-84886946045Q3WOS:000327054300005Q4